Sarika: Created page with "{{infobox drug/testcases/navbox|state=collapsed}} TOC ==vaccine_type== {{testcase table | drug_name = Adenovirus vaccine | INN = | type..."

2022-05-23T05:09:07Z

Created page with "{{infobox drug/testcases/navbox|state=collapsed}} __TOC__ ==vaccine_type== {{testcase table | drug_name = Adenovirus vaccine | INN = | type..."

New page

{{infobox drug/testcases/navbox|state=collapsed}}
__TOC__

==vaccine_type==
{{testcase table
| drug_name = [[Adenovirus vaccine]]
| INN =
| type = vaccine
| image = TEVA adenovirus.jpg
| alt =
| caption = Bottles of the vaccine

| target = [[Adenovirus]]
| vaccine_type = Foo


| pronounce =
| tradename =
| Drugs.com = {{drugs.com|monograph|adenovirus-vaccine}}
| MedlinePlus =
| DailyMedID = c7d0b43c-7250-4809-8a05-fcde5862f076
| pregnancy_AU = 
| pregnancy_AU_comment =
| pregnancy_US = N
| pregnancy_category=
| routes_of_administration = By mouth
| ATCvet =
| ATC_prefix = 
| ATC_suffix =

| legal_AU = 
| legal_AU_comment =
| legal_BR = 
| legal_BR_comment =
| legal_CA = 
| legal_DE = 
| legal_NZ = 
| legal_UK = 
| legal_US = 
| legal_UN = 
| legal_status = 

| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =

| IUPAC_name =
| CAS_number =
| PubChem =
| DrugBank =
| UNII = FKD3DUK39I
| UNII2 = TM54L796SN

| chemical_formula =
| molecular_weight =
}}

==PubChem PID, SID==
{{purge}} '''PID'' {{para|PubChem|3007}}
{{Testcase table
| drug_name = [[Amfetamine]]
| IUPAC_name = {{center|(''RS'')-1-phenylpropan-2-amine}}

| tradename = Adderall, Dyanavel XR, Evekeo, others
| Drugs.com = {{Drugs.com|parent|amphetamine}}
| routes_of_administration= Medical: [[Oral route|oral (ingestion)]], [[Nasal administration|nasal inhalation]], [[intravenous]] Recreational: [[Oral route|oral]], [[Nasal administration|nasal inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravenous]]

| bioavailability = {{nowrap|Oral 75–100%}}
| protein_bound = 15–40%
| excretion = Primarily [[renal]]; [[pH]]-dependent {{nowrap|range: 1–75%}}

| CAS_number = 300-62-9
| ATC_prefix = N06
| ATC_suffix = BA01
| ChEBI = 2679
| PDB_ligand = FRD
| IUPHAR_ligand = 4804

| PubChem = 3007

| DrugBank = DB00182
| ChemSpiderID = 13852819
| NIAID_ChemDB = 018564
| UNII = CK833KGX7E
| KEGG = D07445
| ChEMBL = 405
| synonyms = α-methylphenethylamine

| C=9 | H=13 | N=1
}}

{{purge}} '''SID'' {{para|PubChem|7003}} (?)
{{Testcase table
| drug_name = [[Amfetamine]]
| IUPAC_name = {{center|(''RS'')-1-phenylpropan-2-amine}}

| tradename = Adderall, Dyanavel XR, Evekeo, others
| Drugs.com = {{Drugs.com|parent|amphetamine}}
| routes_of_administration= Medical: [[Oral route|oral (ingestion)]], [[Nasal administration|nasal inhalation]], [[intravenous]] Recreational: [[Oral route|oral]], [[Nasal administration|nasal inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravenous]]

| bioavailability = {{nowrap|Oral 75–100%}}
| protein_bound = 15–40%
| excretion = Primarily [[renal]]; [[pH]]-dependent {{nowrap|range: 1–75%}}

| CAS_number = 300-62-9
| ATC_prefix = N06
| ATC_suffix = BA01
| ChEBI = 2679
| PDB_ligand = FRD
| IUPHAR_ligand = 4804

| PubChemSubstance = 7003

| DrugBank = DB00182
| ChemSpiderID = 13852819
| NIAID_ChemDB = 018564
| UNII = CK833KGX7E
| KEGG = D07445
| ChEMBL = 405
| synonyms = α-methylphenethylamine

| C=9 | H=13 | N=1
}}

==[[Amphetamine]]==
{{purge}} '''FA'''
{{Testcase table
| drug_name = [[Amfetamine]]
| IUPAC_name = {{center|(''RS'')-1-phenylpropan-2-amine}}
| image = Racemic amphetamine 2.svg
| alt = An image of the amphetamine compound
| image2 = D-Amphetamine-3D-balls.png
| alt2 = A 3d image of the D-amphetamine compound
| width = 125px
| width2 = 125px

| pronounce = {{IPAc-en|audio=En-us-amphetamine.ogg|æ|m|ˈ|f|ɛ|t|ə|m|iː|n}}
| tradename = Adderall, Dyanavel XR, Evekeo, others
| Drugs.com = {{Drugs.com|parent|amphetamine}}
| pregnancy_US = C
| legal_AU = Schedule 8
| legal_CA = Schedule I
| legal_DE = Anlage III
| legal_NZ = Class B
| legal_UK = Class B
| legal_US = Schedule II
| legal_UN = Psychotropic Schedule II
| legal_status =
| licence_EU = Amphetamine
| licence_US = Amphetamine
| dependency_liability = [[Physical dependence|Physical]]: none [[Psychological dependence|Psychological]]: moderate
| addiction_liability = Moderate
| routes_of_administration= Medical: [[Oral route|oral (ingestion)]], [[Nasal administration|nasal inhalation]], [[intravenous]] Recreational: [[Oral route|oral]], [[Nasal administration|nasal inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravenous]]

| bioavailability = {{nowrap|Oral 75–100%}}
| protein_bound = 15–40%
| metabolism = Amphetamine only: [[CYP2D6]], [[Dopamine β-hydroxylase|DBH]], [[Flavin-containing monooxygenase|FMO3]]
| metabolites = {{nowrap|[[4-hydroxyamphetamine]]}}, {{nowrap|[[4-hydroxynorephedrine]]}}, {{nowrap|[[4-hydroxyphenylacetone]]}}, [[benzoic acid]], [[hippuric acid]], [[norephedrine]], [[phenylacetone]]
| onset = {{abbr|IR|Immediate release}} dosing: 30–60 minutes<ref name="Medscape Adderall Pharmacology">{{Cite encyclopedia|title = amphetamine/dextroamphetamine | section = Pharmacology |section-url = http://reference.medscape.com/drug/adderall-amphetamine-%20%20dextroamphetamine-342997#10 | website = Medscape | publisher = WebMD | accessdate = 21 January 2016 | quote = Onset of action: 30–60 min }}</ref> {{abbr|XR|Extended release}} dosing: 1.5–2 hours<ref name="Millichap: onset, peak, and duration">{{cite book | author = Millichap JG | editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York, USA | isbn = 9781441913968 | pages = 112 | edition = 2nd | chapter = Chapter 9: Medications for ADHD | quote = Table 9.2 Dextroamphetamine formulations of stimulant medication Dexedrine [Peak:2–3 h] [Duration:5–6 h] ... Adderall [Peak:2–3 h] [Duration:5–7 h] Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ... Adderall XR [Peak:7–8 h] [Duration:12 h] Vyvanse [Peak:3–4 h] [Duration:12 h]}}</ref><ref name="XR onset-duration">{{cite journal | vauthors = Brams M, Mao AR, Doyle RL | title = Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder | journal = Postgrad. Med. | volume = 120 | issue = 3 | pages = 69–88 | date = September 2008 | pmid = 18824827 | doi = 10.3810/pgm.2008.09.1909}}</ref>
| elimination_half-life = {{abbr|D-amph|Dextroamphetamine}}:9–11 hours {{nowrap|{{abbr|L-amph|Levoamphetamine}}:11–14 hours}} [[pH]]-dependent: 8–31 hours
| duration_of_action = {{abbr|IR|Immediate release}} dosing: 3–7 hours<ref name="Narcolepsy guide">{{cite journal | vauthors = Mignot EJ | title = A practical guide to the therapy of narcolepsy and hypersomnia syndromes | journal = Neurotherapeutics | volume = 9 | issue = 4 | pages = 739–752 | date = October 2012 | pmid = 23065655 | pmc = 3480574 | doi = 10.1007/s13311-012-0150-9 }}</ref> {{abbr|XR|Extended release}} dosing: 12 hours
| excretion = Primarily [[renal]]; [[pH]]-dependent {{nowrap|range: 1–75%}}

| CAS_number = 300-62-9
| ATC_prefix = N06
| ATC_suffix = BA01
| ChEBI = 2679
| PDB_ligand = FRD
| IUPHAR_ligand = 4804
| StdInChI = 1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
| StdInChIKey = KWTSXDURSIMDCE-UHFFFAOYSA-N
| PubChem = 3007
| DrugBank = DB00182
| ChemSpiderID = 13852819
| NIAID_ChemDB = 018564
| UNII = CK833KGX7E
| KEGG = D07445
| ChEMBL = 405
| synonyms = α-methylphenethylamine

| C=9 | H=13 | N=1
| molecular_weight = 135.20622 g/mol
| chirality = 1:1 mixture ([[racemate]])
| smiles = NC(CC1=CC=CC=C1)C
| InChI = 1/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3

| density = 0.9±0.1
| melting_point = 11.3
| melting_notes = (predicted)<ref name="Chemspider">{{cite encyclopedia | section-url=http://www.chemspider.com/Chemical-Structure.13852819.html | work=Chemspider | title=Amphetamine | accessdate=6 November 2013 | section=Properties: Predicted – EP{{pipe}}Suite }}</ref>
| boiling_point = 203
| boiling_notes = at 760 [[Millimeter of mercury|mmHg]]
}}

==[[Aspirin]]==
{{purge}}
{{Testcase table
| drug_name = Aspirin
| IUPAC_name = 2-(acetoxy)benzoic acid 
| trivial_name = 2-acetoxybenzoic acid acetylsalicylate acetylsalicylic acid O-acetylsalicylic acid
| image = Aspirin-skeletal.svg
| image2 = Aspirin-B-3D-balls.png
| width = 100px
| width2 = 125px

| pronounce = acetylsalicylic acid {{IPAc-en|ə|ˌ|s|iː|t|əl|ˌ|s|æ|l|ᵻ|ˈ|s|ɪ|l|ᵻ|k}}
| tradename_pronunciation = {{IPAc-en|ə|s|p|i|r|i|n}}
| tradename_synonym = (find example)
| Drugs.com = {{drugs.com|monograph|aspirin}}
| MedlinePlus = a682878
| licence_US = Aspirin
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_US_comment= D in the 3rd trimester
| legal_AU = S2
| legal_AU_comment = except when given intravenously (in which case it is schedule 4), used in animal medicine (schedule 5/6) or when the dose is higher than usual.
| legal_UK = GSL
| legal_US = OTC
| routes_of_administration = Most commonly oral, also rectal, lysine acetylsalicylate may be given [[intravenous therapy|intravenously]] or [[intramuscular injection|intramuscularly]]

| bioavailability = 80–100%<ref name = MSR>{{cite web|title=Zorprin, Bayer Buffered Aspirin (aspirin) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=3 April 2014|url=http://reference.medscape.com/drug/zorprin-bayer-buffered-aspirin-343279#showall}}</ref>
| protein_bound = 80–90%<ref name = MD>{{cite web|title=Aspirin|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=14 January 2014|accessdate=3 April 2014|url=http://www.medicinescomplete.com/mc/martindale/current/2601-s.htm|editor=Brayfield, A}}</ref>
| metabolism = [[Liver|Hepatic]], ([[CYP2C19]] and possibly [[CYP3A]]), some is also hydrolysed to salicylate in the gut wall.<ref name = MD/>
| elimination_half-life = Dose-dependent; 2–3 hours for low doses, 15–30 hours for large doses.<ref name = MD/>
| excretion = Urine (80–100%), sweat, saliva, feces<ref name = MSR/>

| IUPHAR_ligand = 4139
| CAS_number = 50-78-2
| ATC_prefix = A01
| ATC_suffix = AD05
| ATC_supplemental = {{ATC|B01|AC06}}, {{ATC|N02|BA01}}
| PubChem = 2244
| DrugBank = DB00945
| ChemSpiderID = 2157
| UNII = R16CO5Y76E
| KEGG = D00109
| ChEBI = 15365
| ChEMBL = 25
| PDB_ligand = AIN

| C=9 | H=8 | O=4
| molecular_weight = 180.157 g/mol
| smiles = O=C(Oc1ccccc1C(=O)O)C
| InChI = 1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
| StdInChI = 1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
| StdInChIKey = BSYNRYMUTXBXSQ-UHFFFAOYSA-N
| synonyms = 2-acetoxybenzoic acid acetylsalicylate acetylsalicylic acid O-acetylsalicylic acid
| density = 1.40
| melting_point = 135
| boiling_point = 140
| boiling_notes = (decomposes)
| solubility = 3
}}

==[[Methamphetamine]]==
* {{purge}} GA, high number of views
{{Testcase table
| IePAC_name = ''N''-methyl-1-phenylpropan-2-amine
| image = N-Methylamphetamin.svg
| alt = An image of the methamphetamine compound
| image2 = Levomethamphetamine molecule ball from xtal.png
| width2 = 250px
| alt2 = Ball-and-stick model of the methamphetamine molecule

| pronounce = {{IPAc-en|ˌ|m|ɛ|θ|æ|m|ˈ|f|ɛ|t|əm|iː|n}}
| tradename = Desoxyn
| tradename_pronunciation = {{IPAc-en|d|æ|s|x|y|n}} (demo)
| Drugs.com = {{Drugs.com|monograph|methamphetamine-hydrochloride}}
| pregnancy_AU =
| pregnancy_US = C
| dependency_liability = [[Physical dependence|''Physical'']]: none [[Psychological dependence|''Psychological'']]: high
| addiction_liability = Very high
| legal_AU = S8
| legal_CA = Schedule I
| legal_NZ = Class A
| legal_UK = Class A
| legal_US = Schedule II
| legal_UN = Psychotropic Schedule II
| legal_DE = Anlage II
| legal_status = Rx
| licence_US = Methamphetamine
| routes_of_administration= Medical: [[Oral route|oral (ingestion)]], [[intravenous administration|intravenous]]<ref name="RxMethIV">{{Cite book|title = Amphetamine legislation 1971: Hearings, Ninety-second Congress, first session, pursuant to S. Res. 32, section 12, investigation of juvenile delinquency in the United States|url = https://bulk.resource.org/gao.gov/91-513/000050D8.pdf|publisher = U.S. Govt. Print. Off.|date = 1 January 1972|last = United States Congress Senate Committee on the Judiciary Subcommittee to Investigate Juvenile Delinquincy|quote = We made a decision in January of 1969 to cease the manufacture of injectable methamphetamines.|page = 161|access-date = 1 January 2016}}</ref> Recreational: [[Oral route|oral]], [[intravenous administration|intravenous]], [[intramuscular administration|intramuscular]], [[subcutaneous administration|subcutaneous]], [[smoking|smoke inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravaginal administration|vaginal]]

| bioavailability= Oral: 70%<ref name="Bioavailability">{{cite journal | vauthors = Rau T, Ziemniak J, Poulsen D | title = The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury | journal = Prog. Neuropsychopharmacol. Biol. Psychiatry | volume = 64| issue = | pages = 231–6| year = 2015 | pmid = 25724762 | doi = 10.1016/j.pnpbp.2015.02.013 | quote = In humans, the oral bioavailability of methamphetamine is approximately 70% but increases to 100% following intravenous (IV) delivery (Ares-Santos et al., 2013).}}</ref> IV: 100%<ref name="Bioavailability" />
| protein_bound = Varies widely<ref name="Pubchem1">{{cite encyclopedia | title=Methamphetamine | section-url=https://pubchem.ncbi.nlm.nih.gov/compound/1206#section=Toxicity | work=PubChem Compound | publisher = National Center for Biotechnology Information | accessdate=31 December 2013 | section=Toxicity}}</ref>
| metabolism =[[CYP2D6]],<ref name="FDA Pharmacokinetics">{{cite web | title = Adderall XR Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | pages = 12–13 | work = United States Food and Drug Administration |date=December 2013 | accessdate = 30 December 2013 }}</ref> [[Dopamine β-hydroxylase|DBH]],<ref name="DBH ref">{{cite book | title=Foye's Principles of Medicinal Chemistry | year=2013 | publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins | location=Philadelphia | isbn=1609133455 | page=648 | author=Lemke TL, Williams DA, Roche VF, Zito W|edition=7th | quote=Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.}}</ref> [[Flavin-containing monooxygenase|FMO3]],<ref name="FMO">{{cite journal | author = Krueger SK, Williams DE | title = Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism | journal = Pharmacol. Ther. | volume = 106 | issue = 3 | pages = 357–387 |date=June 2005 | pmid = 15922018 | pmc = 1828602 | doi = 10.1016/j.pharmthera.2005.01.001 }}</ref> [[butyrate-CoA ligase|XM-ligase]],<ref name="Benzoic1" /> and [[glycine N-acyltransferase|ACGNAT]]<ref name="Benzoic2" />
| onset = Rapid<ref name=Ri2010/>
| elimination_half-life= 5–30 hours<ref name="Schep"/>
| duration_of_action=10–20 hours<ref name=Ri2010>{{cite book|last1=Riviello|first1=Ralph J.|title=Manual of forensic emergency medicine : a guide for clinicians|date=2010|publisher=Jones and Bartlett Publishers|location=Sudbury, Mass.|isbn=9780763744625|page=41|url=https://books.google.ca/books?id=keng9ELAE2IC&pg=PA41}}</ref>
| excretion = Primarily [[renal]]

| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number=537-46-2
| ATC_prefix=N06
| ATC_suffix=BA03
| ATC_supplemental=
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6809
| IUPHAR_ligand = 4803
| PDB_ligand =
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MYWUZJCMWCOHBA-UHFFFAOYSA-N
| PubChem=1206
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank=DB01577
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1169
| NIAID_ChemDB =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 44RAL3456C
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08187
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1201201


| C=10 | H=15 | N=1
| chirality = 1:1 mixture ([[racemate]])
| smiles = N(C(Cc1ccccc1)C)C
| InChI = 1/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3
| InChIKey = MYWUZJCMWCOHBA-UHFFFAOYAT
| synonyms = {{nowrap|''N''-[[methylamphetamine]]}}, {{nowrap|''N'',α-[[dimethylphenethylamine]]}}, desoxyephedrine
| boiling_point = 212
| boiling_notes = at 760 [[mmHg]]<ref name="Pubchem2">{{cite encyclopedia | title=Methamphetamine | section-url=https://pubchem.ncbi.nlm.nih.gov/compound/1206#section=Chemical-and-Physical-Properties | work=PubChem Compound | publisher = National Center for Biotechnology Information | accessdate=31 December 2013 | section=Chemical and Physical Properties }}</ref>
| melting_point = 3
| melting_notes = (predicted)<ref name="Chemspider" />
}}

{{clear}}

==Order of sections==
* See {{tl|Infobox drug/doc/type-conditional sections/testcases}}
{{clear}}

==Container only==
{{testcase table
| container_only=yes
| drug_name = [[Niacin]]
| INN =
| type =
| image =

| IUPAC_name = abc
| CAS_number = 123-45-67
| PubChem =
| DrugBank =
}}

==Refs==

Template:Infobox drug/testcases9 - Revision history

Sarika: Created page with "{{infobox drug/testcases/navbox|state=collapsed}} __TOC__ ==vaccine_type== {{testcase table | drug_name = Adenovirus vaccine | INN = | type..."

Sarika: Created page with "{{infobox drug/testcases/navbox|state=collapsed}} TOC ==vaccine_type== {{testcase table | drug_name = Adenovirus vaccine | INN = | type..."